trending Market Intelligence /marketintelligence/en/news-insights/trending/CGfnQQ4IFtvHCPG0bAaBxA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Intercept seeks EU approval for liver disease drug Ocaliva

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Intercept seeks EU approval for liver disease drug Ocaliva

Intercept Pharmaceuticals Inc. is seeking EU approval to market Ocaliva as a treatment for nonalcoholic steatohepatitis, a fatal liver disease.

The company's application with the European Medicines Agency is based on a phase 3 trial, called Regenerate, wherein the drug improved patients' fibrosis without worsening the symptoms of nonalcoholic steatohepatitis.

The New York-based biotech also said in a Dec. 13 press release that it expects an advisory committee meeting with the U.S. Food and Drug Administration on April 22, 2020, regarding Ocaliva's label expansion. The regulator was expected to make a decision on Intercept's U.S. application by March 26, 2020, but will now likely push that forward, Intercept said.

Ocaliva is also known as obeticholic acid.